Cognitive and behavioral risk factors for low quality of life in survivors of childhood acute lymphoblastic leukemia

Plas, Ellen van der; Noakes, T. Leigh Spencer; Butcher, Darci T.; Weksberg, Rosanna; Galin-Corini, Laura; Wanstall, Elizabeth A.; Te, Patrick; Hopf, Laura; Guger, Sharon; Schachar, Russell; Itô, Shinya; Nieman, Brian J.

doi:10.1038/s41390-020-01230-7

Cited by 15 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improvements in HRQOL during treatment have also been reported in pediatric cancer populations who undergo intense treatment regimens ( Mitchell et al, 2016 ; Garas et al, 2019 ). As with long-term breast cancer survivors, pediatric cancer survivors also exhibit poor HRQOL later in survivorship ( Kunin-Batson et al, 2014 ; van der Plas et al, 2020 ). It seems reasonable to expect that initial improvements in HRQOL are attributable to a sense of relief that the cancer is being treated ( Garas et al, 2019 ), which, in the short run, may outweigh the negative late effects of treatment ( Criscitiello et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

“…Treatment for breast cancer has been associated with long-term neurocognitive difficulties that are often referred to as “chemo-brain” ( Janelsins et al, 2017 ; Ketterl et al, 2019 ; Eide and Feng, 2020 ; Schroyen et al, 2021 ). Neurocognitive difficulties may encompass memory loss, difficulty concentrating, and other relatively subtle changes that can have a detrimental impact on daily functioning ( Chan et al, 2016 ; Sousa et al, 2020 ) and are negatively associated with HRQOL ( Kunin-Batson et al, 2014 ; Eide and Feng, 2020 ; van der Plas et al, 2020 ; Wagner et al, 2020 ). AYA cancer survivors across various types of cancers have identified neurocognitive deficits as a key issue ( Jim et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterizing Early Changes in Quality of Life in Young Women With Breast Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

IntroductionYounger age at diagnosis is a risk factor for poor health-related quality of life (HRQOL) in long-term breast cancer survivors. However, few studies have specifically addressed HRQOL in young adults with breast cancer (i.e., diagnosed prior to age 40), nor have early changes in HRQOL been fully characterized.MethodsEligible female patients with breast cancer were identified through our local cancer center. To establish HRQOL, patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) around diagnosis and 12 months later. Sociodemographic factors, genetic susceptibility to cancer, tumor- and treatment-related factors, and comorbidities (e.g., depression/anxiety) were abstracted from medical records and the local oncology registry. Mixed-effects models were used to identify changes in FACT-B scores during the first year of treatment and to determine whether any demographic/treatment-related factors modulated changes in scores.ResultsHealth-related quality of life in young patients with breast cancer was within normal limits at baseline, with a FACT-B overall well-being score of 108.5 (95% confidence limits [CI] = 103.7, 113.3). Participants reported slight improvements over a 12-month period: FACT-B overall well-being scores increased 6.6 points (95% CI = 2.1, 11.1, p < 0.01), functional well-being improved 3.0 points (95% CI = 2.0, 4.1, p < 0.01), emotional well-being improved 1.9 points (95% CI = 0.9, 2.8, p < 0.01), and physical well-being improved 1.5 points (95% CI = 0.2, 2.8, p = 0.03), on average. Participants with anxiety/depression at baseline reported greater improvements in FACT-B overall well-being (change: 12.9, 95% CI = 6.4, 9.5) and functional well-being (change: 5.2, 95% CI = 3.5, 6.9) than participants who did not have anxiety/depression at baseline (change in FACT-B overall well-being: 4.9, 95% CI = 0.2, 9.7; change in functional well-being: 2.3, 95% CI = 1.1, 3.4). Marital status, reconstructive surgery, and baseline clinical staging were also significantly associated with changes in aspects of HRQOL, although their impact on change was relatively minimal.ConclusionYoung women with breast cancer do not report HRQOL concerns during the first year of treatment. Improvements in HRQOL during the first year of treatment may be attributable to a sense of relief that the cancer is being treated, which, in the short run, may outweigh the negative late effects of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Characterizing Early Changes in Quality of Life in Young Women With Breast Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…As long-term survival rates continue to improve in patients diagnosed with pediatric ALL, optimizing neurocognitive functioning is becoming increasingly important given its potential importance for educational attainment, vocational success, and overall quality of life. 56 Fatigue and sleep disturbances are frequent sources of distress during pediatric cancer treatment. 8,9 The current study provides new insight into the potential for sleep and fatigue to influence long-term neurocognitive performance.…”

Section: Discussionmentioning

confidence: 99%

Association between fatigue and sleep disturbances during treatment for pediatric acute lymphoblastic leukemia and posttreatment neurocognitive performance

Vásquez

Escalante

Raghubar

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Survivors of pediatric acute lymphoblastic leukemia (ALL) are at increased risk of neurocognitive weakness in the areas of attention, executive function, and processing speed. Although fatigue and sleep disturbances are frequent complications of ALL therapy and associated with cognitive functions, the impact of fatigue and sleep profiles during active ALL treatment on posttreatment neurocognitive performance has received limited attention. Methods: Pediatric patients (n = 120) with ALL (diagnosed 2011-2016) who completed fatigue and sleep questionnaires at four time points during active treatment were enrolled in a study of neurocognitive performance. Latent class growth analysis identified subgroups of patients with similar sleep and fatigue profiles during treatment. Neurocognitive performance collected >6 months post treatment on 40 participants was compared between latent classes using multivariable linear regression models. Results: Participants (57.5% male and 79.1% Hispanic or non-Hispanic White) were classified into one of two fatigue and sleep profiles: Class 1 characterized by mild fatigue and sleep disturbances during treatment (50.8%), and Class 2 characterized by higher levels of fatigue and sleep disturbances (49.2%). Posttreatment cognitive performance was in the normal range for most measures, but significantly below normative means for executive function, verbal short-term memory, attention, and distractability measures. Compared to Class 1, Class 2 demonstrated significantly (p < .05) poorer posttreatment neurocognitive performance, particularly in measures of attention. Conclusions: Our findings indicate that fatigue and sleep disturbances during the first year of pediatric ALL therapy may impact long-term neurocognitive performance.

show abstract

“…People withsmoking, exposure to ionizing radiation and chemicals like benzene, previous chemotherapy, and Down syndrome are predisposed to the disease(8). Moreover, individuals with a family history of leukemia have a higher risk of developingthe disease (9). The therapeutic measures for this disease include chemotherapy, radiotherapy, targeted therapies, bone marrow transplantation, or a combination of these methods.…”

Section: Introductionmentioning

confidence: 99%

Seropositivity for CMV, EBV, HBV, HCV, and HIV in Leukemia Patients and Its Relationship with Cytogenetic Changes

Eslami

Falahati

Siroosbakht

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: Leukemias are involving the bone marrow and the soft tissues in inner parts of the bones, where new blood cells are formed. This malignancy is the most common pediatric cancer, which its etiologic causes are not well understood. This multifactorial disease is believed to linked with genetic and non-hereditary environmental factors. Cytogenic analyses of chromosomal abnormalities provide diagnostic and prognostic values in leukemia patients. Given the high prevalence of viral diseases and clinical suspicions on the relationship between certain viral infections and leukemia, it is necessary to investigate this possible relationship, especially in third-world countries. The present study recruited 65 children with leukemia (AML, CML, or ALL) who were presented to two tertiary hospitals. At first, all the patients underwent testing for HBV, HCV, CMV, EBV, and HIV. Bone marrow specimens were studied for identifying possible chromosomal abnormalities in cytogenic investigations. According to our findings, there was a relationship between incidence of leukemia, the 12:21 chromosomal translocation and CMV infection. Therefore, preventing CMV infection can lead to a reduced incidence of leukemia. It is expected that the findings of this study enlighten the scientists to conduct more extensive research on the relationship between viral diseases and leukemia in third-world countries.Method:The present study recruited 65 children with leukemia (AML, CML, or ALL) who were presented to two tertiary hospitals. At first, all the patients underwent testing forHBV, HCV, CMV, EBV, and HIV. Bone marrow specimens were studied for identifying possible chromosomal abnormalities in cytogenic investigations.Result:According to our findings,there was a relationship between the incidence of leukemia,the 12:21 chromosomal translocation, and CMV infection.Therefore, preventing CMV infection can lead to a reducedincidence of leukemia.Conclusion:In this study, we demonstrated that leukemia is relevant to the 12:21 chromosomal translocation and CMV virus infections, So the reduction in leukemia prevalence is dependent on the prevention of CMV disease. It is expected that the findings ofthis studyenlighten the scientists to conduct more extensive researchon the relationship between viral diseasesand leukemia in third-world countries.Trial registrations:Clinical trial registration code:IR.AJAUMS.REC.1399.161Evaluated by: AJA UNIVERSITY OF MEDICAL SCIENCESApproval Date:2020-11-15Approval statement: The project was found to be in accordance with the ethical principles and the national norms and standards for conducting Medical Research in Iran.

show abstract

Cognitive and behavioral risk factors for low quality of life in survivors of childhood acute lymphoblastic leukemia

Cited by 15 publications

References 38 publications

Characterizing Early Changes in Quality of Life in Young Women With Breast Cancer

Characterizing Early Changes in Quality of Life in Young Women With Breast Cancer

Association between fatigue and sleep disturbances during treatment for pediatric acute lymphoblastic leukemia and posttreatment neurocognitive performance

Seropositivity for CMV, EBV, HBV, HCV, and HIV in Leukemia Patients and Its Relationship with Cytogenetic Changes

Contact Info

Product

Resources

About